BIOMAT Database Logo BIOMAT Database Logo

BRL 35135, a potent and selective atypical beta-adrenoceptor agonist. 1992

M A Cawthorne, and M V Sennitt, and J R Arch, and S A Smith
Diabetes Programme, SmithKline Beecham Pharmaceuticals, Great Burgh, Epsom, Surrey, UK.

BRL 35135, via its active deesterified metabolite BRL 37344, is a potent example of a new group of beta-adrenoceptor agonists that stimulate selectively a novel beta adrenoceptor that was originally shown to be present in brown adipose tissue in rodents. BRL 35135 produces a dose-related increase in energy expenditure in rodents and, in genetically obese (ob/ob) mice, a dose of 0.5 mg.kg-1.d-1 has significant antiobesity activity. This weight loss is entirely due to loss of fat; muscle protein is preserved. In studies in nonobese men, BRL 35135 (0.1 mg/kg) increased both resting metabolic rate and the thermic response to a glucose load. BRL 35135 is effective in improving glucose tolerance in genetically obese (ob/ob) mice and obese Zucker (fa/fa) rats at doses that have no significant antiobesity activity. The improved glucose tolerance is the result of significant improvement in insulin sensitivity. In 10-d studies in obese and diabetic patients, BRL 35135 produced improvements in glucose tolerance and insulin sensitivity.

UI MeSH Term Description Entries
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D010627 Phenethylamines A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed) Phenylethylamines
D001833 Body Temperature Regulation The processes of heating and cooling that an organism uses to control its temperature. Heat Loss,Thermoregulation,Regulation, Body Temperature,Temperature Regulation, Body,Body Temperature Regulations,Heat Losses,Loss, Heat,Losses, Heat,Regulations, Body Temperature,Temperature Regulations, Body,Thermoregulations
D002001 Adipose Tissue, Brown A thermogenic form of adipose tissue composed of BROWN ADIPOCYTES. It is found in newborns of many species including humans, and in hibernating mammals. Brown fat is richly vascularized, innervated, and densely packed with MITOCHONDRIA which can generate heat directly from the stored lipids. Brown Fat,Hibernating Gland,Brown Adipose Tissue,Fat, Brown,Tissue, Brown Adipose
D004734 Energy Metabolism The chemical reactions involved in the production and utilization of various forms of energy in cells. Bioenergetics,Energy Expenditure,Bioenergetic,Energy Expenditures,Energy Metabolisms,Expenditure, Energy,Expenditures, Energy,Metabolism, Energy,Metabolisms, Energy
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000318 Adrenergic beta-Agonists Drugs that selectively bind to and activate beta-adrenergic receptors. Adrenergic beta-Receptor Agonists,beta-Adrenergic Agonists,beta-Adrenergic Receptor Agonists,Adrenergic beta-Agonist,Adrenergic beta-Receptor Agonist,Betamimetics,Receptor Agonists, beta-Adrenergic,Receptors Agonists, Adrenergic beta,beta-Adrenergic Agonist,beta-Adrenergic Receptor Agonist,Adrenergic beta Agonist,Adrenergic beta Agonists,Adrenergic beta Receptor Agonist,Adrenergic beta Receptor Agonists,Agonist, Adrenergic beta-Receptor,Agonist, beta-Adrenergic,Agonist, beta-Adrenergic Receptor,Agonists, Adrenergic beta-Receptor,Agonists, beta-Adrenergic,Agonists, beta-Adrenergic Receptor,Receptor Agonist, beta-Adrenergic,Receptor Agonists, beta Adrenergic,beta Adrenergic Agonist,beta Adrenergic Agonists,beta Adrenergic Receptor Agonist,beta Adrenergic Receptor Agonists,beta-Agonist, Adrenergic,beta-Agonists, Adrenergic,beta-Receptor Agonist, Adrenergic,beta-Receptor Agonists, Adrenergic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

M A Cawthorne, and M V Sennitt, and J R Arch, and S A Smith
Acute effects of the beta 3-adrenoceptor agonist, BRL 35135, on tissue glucose utilisation.
February 1995, British journal of pharmacology,
M A Cawthorne, and M V Sennitt, and J R Arch, and S A Smith
Potentiation of the anti-obesity effect of the selective beta 3-adrenoceptor agonist BRL 35135 in obese Zucker rats by exercise.
December 1994, British journal of pharmacology,
M A Cawthorne, and M V Sennitt, and J R Arch, and S A Smith
Carazolol: a potent, selective beta 3-adrenoceptor agonist.
November 1995, European journal of pharmacology,
M A Cawthorne, and M V Sennitt, and J R Arch, and S A Smith
Beta-adrenoceptor subtypes mediating the airways response to BRL 35135 in man.
December 1993, British journal of clinical pharmacology,
M A Cawthorne, and M V Sennitt, and J R Arch, and S A Smith
Beta-adrenoceptor subtypes mediating the metabolic effects of BRL 35135 in man.
March 1994, Clinical science (London, England : 1979),
M A Cawthorne, and M V Sennitt, and J R Arch, and S A Smith
Effect of the beta-adrenoceptor agonist BRL-35135 on development of obesity in suckling Zucker (fa/fa) rats.
June 1995, The American journal of physiology,
M A Cawthorne, and M V Sennitt, and J R Arch, and S A Smith
The effects of the beta3-adrenoceptor agonist BRL 35135 on UCP isoform mRNA expression.
November 1998, Biochemical and biophysical research communications,
M A Cawthorne, and M V Sennitt, and J R Arch, and S A Smith
Effects of BRL 35135, a beta-adrenoceptor agonist with novel selectivity, on glucose tolerance and insulin sensitivity in obese subjects.
January 1989, International journal of obesity,
M A Cawthorne, and M V Sennitt, and J R Arch, and S A Smith
Heterogenous activity of BRL 35135, a beta 3-adrenoceptor agonist, in thermogenesis and increased blood flow in brown adipose tissue in anaesthetized rats.
July 1994, Clinical and experimental pharmacology & physiology,
M A Cawthorne, and M V Sennitt, and J R Arch, and S A Smith
Clinical studies with the beta-adrenoceptor agonist BRL 26830A.
January 1992, The American journal of clinical nutrition,
Copied contents to your clipboard!